Xolair Injection 150 Mg 1 Vial
Xolair 150 mg Injection (Omalizumab) is a monoclonal antibody therapy licensed for chronic spontaneous urticaria (CSU) and moderate to severe allergic asthma that does not respond adequately to standard treatments. By binding to IgE antibodies, Xolair stops the allergic cascade and reduces symptoms like wheals, itching, and airway inflammation.
Each vial contains 150 mg of Omalizumab for subcutaneous injection, typically administered every 2 or 4 weeks, based on patient weight and baseline IgE levels. Healthcare professionals give injections in a clinical setting to monitor possible allergic reactions post-dose.
Xolair helps reduce reliance on oral antihistamines or corticosteroids in urticaria, and decreases severe asthma exacerbations, improving quality of life. Patients experience fair onset of action within weeks of starting therapy.
Common side effects include injection-site reactions, headache, and mild viral infections. Rare but serious effects may involve anaphylaxis—patients remain under observation after each dose.
Store unused vials in a refrigerator at 2°C to 8°C, protect from light, and allow them to reach room temperature before injection.
Xolair (Omalizumab) 150 mg Injection is a recombinant humanized monoclonal antibody that binds to the constant region of free IgE. It blocks IgE from attaching to mast cells and basophils—halting the allergic chain reaction.
Indications:
Chronic spontaneous urticaria (CSU): recommended in adults and adolescents (≥12 years) who do not respond to H1-antihistamines. Xolair reduces the severity and frequency of itching and hives.
Moderate to severe allergic asthma: for patients aged ≥6 years with elevated IgE levels and inadequate asthma control on high-dose inhaled corticosteroids.
Dosage & Administration:
CSU: 150 mg subcutaneously every 4 weeks. May increase to 300 mg based on response.
Asthma: Dose (75–375 mg) and interval (2–4 weeks) depend on body weight and IgE titre.
All doses should be administered by trained professionals, with observation for at least 2 hours after the first three injections and at least 30 minutes thereafter.
Efficacy & Benefits:
Urticaria: significantly fewer flare-ups, less itching, and reduced antihistamine usage within weeks.
Asthma: fewer exacerbations, improved lung function, reduced inhaled corticosteroid dose, better symptoms, and quality of life.
Side Effects & Precautions:
Common: injection site pain, headache, mild upper respiratory infections.
Serious (rare): anaphylaxis, serum sickness–like reactions, cardiovascular events.
Contraindicated in patients with known hypersensitivity. Patients should update vaccination status—especially for herpes zoster and respiratory viruses—prior to therapy.
Storage & Handling:
Refrigerate between 2–8 °C, protect from light, and do not freeze. Before injection, allow vial to reach room temperature (15–25 °C) for 20–30 minutes. Once opened, discard unused contents.
Xolair offers targeted therapy for chronic urticaria and allergic asthma, reducing symptoms and improving treatment outcomes where conventional therapies fail.
For more biologics, allergy, and respiratory medications, explore our Medicine Category. Visit our full product lineup at the online pharmacy shop.
Related products
Reviews
Clear filtersThere are no reviews yet.